MX2021000861A - Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos. - Google Patents

Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos.

Info

Publication number
MX2021000861A
MX2021000861A MX2021000861A MX2021000861A MX2021000861A MX 2021000861 A MX2021000861 A MX 2021000861A MX 2021000861 A MX2021000861 A MX 2021000861A MX 2021000861 A MX2021000861 A MX 2021000861A MX 2021000861 A MX2021000861 A MX 2021000861A
Authority
MX
Mexico
Prior art keywords
molecular
diseases
conditions
treating fibrous
fibrous adhesions
Prior art date
Application number
MX2021000861A
Other languages
English (en)
Inventor
Christopher Michael Kevin Springate
Ian Millet
Sailesh Haresh Daswani
Hesong Sun
Original Assignee
Arc Medical Devices Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arc Medical Devices Inc filed Critical Arc Medical Devices Inc
Publication of MX2021000861A publication Critical patent/MX2021000861A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Sustainable Development (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Artificial Filaments (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Composiciones de fucanos de alto peso molecular que comprenden un fucano terapéuticamente eficaz y médicamente aceptable en una composición, en donde el fucano, por ejemplo, tiene una distribución de peso molecular en la que más del 60% en p/p de la composición tiene un peso molecular por arriba de 100 kDa.
MX2021000861A 2018-07-27 2019-07-24 Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos. MX2021000861A (es)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862711364P 2018-07-27 2018-07-27
US201862711335P 2018-07-27 2018-07-27
US201862711372P 2018-07-27 2018-07-27
US201862713399P 2018-08-01 2018-08-01
US201862713413P 2018-08-01 2018-08-01
US201862713392P 2018-08-01 2018-08-01
US201862722137P 2018-08-23 2018-08-23
US201862722135P 2018-08-23 2018-08-23
US201862755318P 2018-11-02 2018-11-02
US201862755311P 2018-11-02 2018-11-02
US201862755328P 2018-11-02 2018-11-02
US201962793514P 2019-01-17 2019-01-17
US201962793654P 2019-01-17 2019-01-17
US201962861235P 2019-06-13 2019-06-13
US201962861223P 2019-06-13 2019-06-13
US201962861228P 2019-06-13 2019-06-13
PCT/CA2019/051027 WO2020019078A1 (en) 2018-07-27 2019-07-24 High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions

Publications (1)

Publication Number Publication Date
MX2021000861A true MX2021000861A (es) 2021-03-26

Family

ID=69180222

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2021000862A MX2021000862A (es) 2018-07-27 2019-07-24 Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos.
MX2021000864A MX2021000864A (es) 2018-07-27 2019-07-24 Fucanos altos en sulfato para el tratamiento de adhesiones fibrosas.
MX2021000860A MX2021000860A (es) 2018-07-27 2019-07-24 Composiciones de fucano con bajo contenido de endotoxina y métodos para obtenerlas.
MX2021000861A MX2021000861A (es) 2018-07-27 2019-07-24 Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos.
MX2021000863A MX2021000863A (es) 2018-07-27 2019-07-24 Composiciones de fucano altamente purificado y/o modificado para el tratamiento de adhesiones fibrosas.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2021000862A MX2021000862A (es) 2018-07-27 2019-07-24 Fucanos altamente purificados para el tratamiento de adherencias fibrosas y métodos para obtenerlos.
MX2021000864A MX2021000864A (es) 2018-07-27 2019-07-24 Fucanos altos en sulfato para el tratamiento de adhesiones fibrosas.
MX2021000860A MX2021000860A (es) 2018-07-27 2019-07-24 Composiciones de fucano con bajo contenido de endotoxina y métodos para obtenerlas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000863A MX2021000863A (es) 2018-07-27 2019-07-24 Composiciones de fucano altamente purificado y/o modificado para el tratamiento de adhesiones fibrosas.

Country Status (15)

Country Link
US (5) US11446326B2 (es)
EP (5) EP3829600A4 (es)
JP (10) JP2021531392A (es)
KR (5) KR20210035172A (es)
CN (5) CN112513104B (es)
AU (10) AU2019312088B2 (es)
BR (5) BR112021000617A2 (es)
CA (5) CA3106456A1 (es)
IL (5) IL280168A (es)
MX (5) MX2021000862A (es)
PH (4) PH12021550104A1 (es)
SG (5) SG11202100390SA (es)
TW (4) TW202007399A (es)
WO (5) WO2020019077A1 (es)
ZA (3) ZA202100272B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100390SA (en) 2018-07-27 2021-02-25 Arc Medical Devices Inc High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
EP4387630A1 (en) * 2021-08-20 2024-06-26 ARC Medical Inc. Fucan and modified fucan compositions for the treatment of conditions related to capsular contracture and to inhibiting fibrous growth around or on transplants
TWI829020B (zh) * 2021-10-08 2024-01-11 中華海洋生技股份有限公司 小分子褐藻醣膠用於製備子宮內膜異位症藥物和保健食品之用途
CN114392399B (zh) * 2022-01-26 2022-09-02 青岛琛蓝海洋生物工程有限公司 一种木葡聚糖防粘连膜及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461873A (en) 1982-06-22 1984-07-24 Phillips Petroleum Company Ethylene polymer blends
JPH0491027A (ja) * 1990-08-02 1992-03-24 Taiho Yakuhin Kogyo Kk 抗ヒト免疫不全症ウィルス剤
DE4213963A1 (de) 1992-04-28 1993-11-04 Seitz Filter Werke Verfahren und vorrichtung zur reinigung von abwasser
CA2185324A1 (en) * 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5772900A (en) 1994-06-22 1998-06-30 Noritake Co., Limited Method and apparatus for reclaiming used working fluid
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
IT1288713B1 (it) 1996-12-18 1998-09-23 Crinos Industria Farmaco Fucani a basso peso molecolare aventi attivita' anticoagulante antitrombinica e antitrombotica
JPH10195106A (ja) * 1997-01-13 1998-07-28 Masakuni Tako 養殖イトモズクからの純度の高いフコイダンの製造法
WO2001081560A1 (fr) * 2000-04-21 2001-11-01 Takara Bio Inc. Sulfate de glucuronofucane
US6868715B1 (en) 2000-09-20 2005-03-22 General Electric Company Method and apparatus for rapid determination of polymer molecular weight
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
EP1424396A4 (en) * 2001-09-05 2006-08-16 Takara Bio Inc GENE OF THE ENZYME OF DIGESTION OF FUCOGALACTANE SULFATE
AU2002348395A1 (en) 2001-10-23 2003-05-06 Waters Investments Limited System and method for determining radius of gyration, molecular weight, and intrinsic viscosity of a polymeric distribution using gel permeation chromatography and light-scattering detection
SE0200507D0 (sv) 2002-02-21 2002-02-21 Biovitrum Ab Chromatographic method
EP1514923A4 (en) 2002-06-20 2005-12-21 Takara Bio Inc ENZYME FOR REMOVING SEACURATE STREAMING SULPHATED FUCAN
US20040014179A1 (en) * 2002-06-20 2004-01-22 Novozymes A/S Flocculation with divalent salt
RU2247574C2 (ru) 2002-12-26 2005-03-10 Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН Средство, обладающее антикоагулянтным и иммунотропным действием
JP2007504273A (ja) 2003-05-30 2007-03-01 エーアールシー ファーマシューティカルズ，インク． 種々の作用剤を用いた、線維性癒着の抑制に関する医薬組成物及び方法
KR100695779B1 (ko) * 2004-09-20 2007-03-19 배태진 푸코이단을 생산하는 미생물 및 이를 이용한 푸코이단의생산 방법
DK1809303T3 (da) * 2004-09-23 2019-06-11 Arc Medical Devices Inc Farmaceutisk sammensætning og metoder i relation til hæmning af fibrøs adhæsion eller inflammatoriske lidelser ved brug af lavsulfat-fucan
KR100623001B1 (ko) * 2004-10-11 2006-09-19 한국식품연구원 갈조류로 부터 항암 및 항고지혈 활성을 갖는 식품소재용 라미나란과 휴코이단의 일괄 분리 정제방법
CN1305885C (zh) * 2004-12-31 2007-03-21 中国科学院海洋研究所 海带中l－褐藻糖的制备方法
US20090105190A1 (en) * 2005-03-01 2009-04-23 Koji Hatano Method for Producing Fucoidan, Fucoidan, and Fucoidan-Containing Composition
WO2007028256A2 (en) * 2005-09-09 2007-03-15 Les Biotechnologies Oceanova Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
CA2636983A1 (en) * 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
US7803629B2 (en) 2006-06-27 2010-09-28 Chevron Phillips Chemical Company, Lp Method for employing SEC-FTIR data to predict mechanical properties of polyethylene
CN1985846B (zh) 2006-09-04 2011-08-31 北京世纪博康医药科技有限公司 褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途
CN1985847B (zh) * 2006-09-04 2011-10-05 北京世纪博康医药科技有限公司 低分子量褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途
KR100705975B1 (ko) 2006-10-02 2007-04-10 이엔지바이오 주식회사 생체이용성 후코이단 및 그의 제조방법
CN101011411A (zh) * 2006-12-08 2007-08-08 北京世纪博康医药科技有限公司 褐藻多糖硫酸酯在制备治疗肝脏疾病的药物中的用途
US20100075751A1 (en) * 2007-02-19 2010-03-25 Wms Gaming Inc. Network diagnostics in a wagering game system
EP3409694A1 (en) 2007-02-23 2018-12-05 Baxalta GmbH Process methods for fucoidan purification from seaweed extracts
CN100540568C (zh) * 2007-04-20 2009-09-16 中国科学院海洋研究所 一种提取褐藻多糖硫酸酯的方法
US7818109B2 (en) 2007-10-23 2010-10-19 Bose Corporation Methods and apparatus for securing an active vehicle seat
CN101156664B (zh) 2007-11-21 2010-08-11 上海理工大学 从海带提碘碱炼液中提取岩藻多糖的方法
SI2246336T1 (sl) 2008-02-28 2020-09-30 Nippon Shinyaku Co., Ltd. Inhibitor fibroze
WO2010110223A1 (ja) 2009-03-23 2010-09-30 国立大学法人鳥取大学 抗腫瘍作用を有するフコイダン
KR20100138440A (ko) * 2009-06-25 2010-12-31 주식회사 한립생명공학 푸코이단 분해 효소 및 이의 제조방법
JO3676B1 (ar) 2009-07-27 2020-08-27 Arc Medical Devices Inc مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
CN101659709B (zh) 2009-09-18 2011-09-07 集美大学 岩藻聚糖的制备方法
US8632991B2 (en) 2010-01-14 2014-01-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
US10786528B2 (en) * 2010-02-22 2020-09-29 Helen Fitton Anti-viral formulations
US9481859B2 (en) 2010-07-22 2016-11-01 Heineken Supply Chain B.V. Method of stabilizing yeast fermented beverages
EP3235557A1 (en) 2011-09-01 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
JP2013180994A (ja) 2012-03-02 2013-09-12 Kokando:Kk 単純ヘルペスウイルス２型感染予防剤およびインフルエンザウイルス感染治療剤
DK2838643T3 (da) 2012-04-20 2021-07-12 Vlaamse Instelling Voor Tech Onderzoek Vito Forbedret kemisk fortyndingsreaktionsproces med membranseparationstrin
KR20140033692A (ko) * 2012-09-10 2014-03-19 차의과학대학교 산학협력단 고분자량의 푸코이단을 포함하는 미백용 조성물
CN202778304U (zh) 2012-09-11 2013-03-13 湖南金能机械制造有限公司 一种循环泵分流搅拌装置
JP2014124579A (ja) 2012-12-26 2014-07-07 Sekisui Chem Co Ltd 有機排水の処理装置
AU2013375786B2 (en) 2013-01-25 2018-10-04 Marinova Pty Ltd Treatment methods
FR3020570B1 (fr) * 2014-04-30 2017-07-21 Pierre Fabre Dermo-Cosmetique Association d'un acide hyaluronique et d'un polysaccharide sulfate
KR101635268B1 (ko) 2014-07-23 2016-06-30 제주대학교 산학협력단 후코이단을 함유하는 비장세포의 생존 및 기능 증진 효과를 가진 면역증강용 조성물
KR101531479B1 (ko) 2014-11-21 2015-06-26 세원셀론텍(주) 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법
CN105732834A (zh) * 2014-12-10 2016-07-06 黑龙江众生生物工程有限公司 一种褐藻岩藻聚糖硫酸酯提取纯化方法
CN104586878A (zh) 2015-01-14 2015-05-06 青岛海洋生物医药研究院股份有限公司 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用
WO2016117024A1 (ja) 2015-01-20 2016-07-28 三菱化学エンジニアリング株式会社 酸素を含有するマイクロナノバブル及び殺菌性を有する気体を含有するマイクロナノバブルの供給装置を備えた生物反応装置
SG11201708664SA (en) 2015-04-24 2017-11-29 Univ Nanyang Tech Method and apparatus for assessing a state of fouling of a reverse osmosis system
WO2017042603A1 (en) 2015-09-07 2017-03-16 Total Sa Method for determining the weight-average molecular weight of a water-soluble high molecular weight polymer
CN105399848B (zh) 2015-11-20 2017-11-17 中国科学院上海药物研究所 一种岩藻聚糖硫酸酯、其制备方法和用途
CN106832022A (zh) 2015-12-04 2017-06-13 威海市宇王集团有限公司 一种提取岩藻聚糖硫酸酯的方法
CN106957374A (zh) * 2016-01-12 2017-07-18 中国科学院过程工程研究所 一种从藻类中提取褐藻糖胶和褐藻胶的方法
WO2017160739A1 (en) 2016-03-14 2017-09-21 Pendo TECH Processing system for multiple tangential flow filtration stations in bioprocessing applications
CN107382660A (zh) 2016-05-14 2017-11-24 江西理文化工有限公司 一种二氟一氯甲烷生产中气相除酸方法
US10139378B2 (en) 2016-05-16 2018-11-27 Exxonmobil Chemical Patents Inc. Methods of determining molecular weight and comonomer characteristics of a copolymer in polymer blends
KR101950246B1 (ko) 2017-02-14 2019-02-22 (주)필로스 비상용 이동식 막여과 정수 장치
CN107382666A (zh) * 2017-07-26 2017-11-24 中国水产科学研究院黄海水产研究所 一种海带漂烫水中可溶性有机物的节能高效提取方法
SG11202100390SA (en) * 2018-07-27 2021-02-25 Arc Medical Devices Inc High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
KR20210131988A (ko) 2019-03-05 2021-11-03 에이알시 메디컬 디바이시즈 인코포레이션 점성 조성물의 접선유동여과를 위한 시스템과 방법
AU2020232990B2 (en) 2019-03-05 2021-04-29 Arc Medical Devices Inc. Method for predicting a molecular weight distribution of a biopolymer blend

Also Published As

Publication number Publication date
ZA202100272B (en) 2022-08-31
BR112021000626A2 (pt) 2021-04-13
MX2021000860A (es) 2021-07-15
KR20210036914A (ko) 2021-04-05
AU2019312088A1 (en) 2021-02-04
JP7302831B2 (ja) 2023-07-04
CN112770763A (zh) 2021-05-07
AU2019310194A1 (en) 2021-02-04
BR112021000621A2 (pt) 2021-04-13
IL280168A (en) 2021-03-01
JP2022177065A (ja) 2022-11-30
SG11202100393TA (en) 2021-02-25
PH12021550105A1 (en) 2021-10-04
ZA202100275B (en) 2022-08-31
CN112513103B (zh) 2023-04-25
JP2021531392A (ja) 2021-11-18
JP2022514723A (ja) 2022-02-15
JP2021532137A (ja) 2021-11-25
TW202019443A (zh) 2020-06-01
US20210299159A1 (en) 2021-09-30
SG11202100397UA (en) 2021-02-25
TW202020035A (zh) 2020-06-01
EP3830183A1 (en) 2021-06-09
IL280183A (en) 2021-03-01
MX2021000863A (es) 2021-07-15
BR112021000631A2 (pt) 2021-04-06
WO2020019078A1 (en) 2020-01-30
AU2019310360B2 (en) 2021-10-28
MX2021000864A (es) 2021-03-26
IL280174A (en) 2021-03-01
CN112513165A (zh) 2021-03-16
WO2020019081A1 (en) 2020-01-30
TW202019444A (zh) 2020-06-01
EP3830139A1 (en) 2021-06-09
WO2020019080A1 (en) 2020-01-30
AU2019310656B2 (en) 2022-03-10
SG11202100391VA (en) 2021-02-25
KR20210040360A (ko) 2021-04-13
US11628183B2 (en) 2023-04-18
IL280172A (en) 2021-03-01
SG11202100388TA (en) 2021-02-25
EP3830182A1 (en) 2021-06-09
US20210292441A1 (en) 2021-09-23
EP3830138A4 (en) 2023-02-08
EP3830183A4 (en) 2022-06-08
PH12021550104A1 (en) 2021-10-04
CN112513165B (zh) 2023-04-25
AU2019310360A1 (en) 2021-02-04
AU2022203958A1 (en) 2022-06-23
CN112533989A (zh) 2021-03-19
JP2022177066A (ja) 2022-11-30
BR112021000617A2 (pt) 2021-04-06
AU2022200569A1 (en) 2022-02-17
JP2021531305A (ja) 2021-11-18
JP2022177054A (ja) 2022-11-30
US20210290660A1 (en) 2021-09-23
CA3106466A1 (en) 2020-01-30
JP2021533218A (ja) 2021-12-02
EP3829600A4 (en) 2022-06-15
IL280169A (en) 2021-03-01
JP7477238B2 (ja) 2024-05-01
PH12021550106A1 (en) 2021-10-04
AU2022200771A1 (en) 2022-02-24
EP3830182A4 (en) 2022-06-29
CA3106464A1 (en) 2020-01-30
US11642368B2 (en) 2023-05-09
CA3106456A1 (en) 2020-01-30
SG11202100390SA (en) 2021-02-25
WO2020019079A1 (en) 2020-01-30
CN112513104B (zh) 2023-06-13
US11419891B2 (en) 2022-08-23
PH12021550103A1 (en) 2021-10-04
AU2022201112A1 (en) 2022-03-10
US20210290658A1 (en) 2021-09-23
KR20210036913A (ko) 2021-04-05
CN112513104A (zh) 2021-03-16
AU2019310656A1 (en) 2021-02-04
JP2023085302A (ja) 2023-06-20
EP3830139A4 (en) 2022-04-27
US11938145B2 (en) 2024-03-26
KR20210040359A (ko) 2021-04-13
AU2019312088B2 (en) 2021-11-18
CN112513103A (zh) 2021-03-16
CA3106458A1 (en) 2020-01-30
AU2019311591A1 (en) 2021-02-04
JP2023081932A (ja) 2023-06-13
ZA202100270B (en) 2022-08-31
EP3830138A1 (en) 2021-06-09
EP3829600A1 (en) 2021-06-09
AU2019311591B2 (en) 2021-11-04
AU2019310194B2 (en) 2021-07-22
JP7272707B2 (ja) 2023-05-12
US11446326B2 (en) 2022-09-20
KR20210035172A (ko) 2021-03-31
US20210290659A1 (en) 2021-09-23
TW202007399A (zh) 2020-02-16
WO2020019077A1 (en) 2020-01-30
BR112021000623A2 (pt) 2021-04-13
CA3106465A1 (en) 2020-01-30
MX2021000862A (es) 2021-07-21
AU2021254608A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2021000861A (es) Fucanos de alto peso molecular para tratar adhesiones fibrosas y otras enfermedades y padecimientos.
GB2554296A (en) Antithrombin-heparin compositions and methods
MX2020001912A (es) Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
SA517390513B1 (ar) تركيبات تشتمل على سلالات بكتيرية
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
MX2022011550A (es) Composiciones y métodos para inhibir la expresión de angptl3.
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
MX2022003422A (es) Derivado de heteroarilamidopiridinol y composicion farmaceutica que comprende el mismo como ingrediente activo para prevencion o tratamiento de enfermedad autoinmune.
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
MX2022003398A (es) Composicion micelar inmunoestimulante.
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
MX2021001019A (es) Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
MX2022000607A (es) Composiciones y metodos para el pretratamiento de metales.
MX2017001900A (es) Composicion nasal con capacidades de formacion de pelicula.